Promising combo for rare breast cancer stalls after single patient

This early-phase study aimed to find the best dose and test the safety of combining dasatinib (a targeted cancer drug) with icosapent ethyl (an omega-3 fatty acid) in people with metastatic triple-negative inflammatory breast cancer, a rare and aggressive form. Only one participant was enrolled before the study was terminated, so no conclusions about effectiveness could be drawn. The goal was to shrink tumors, but the trial ended too early to provide meaningful results.